Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003860 | 1.00 | CFTR (0.52) | CFTRKMT2A | |
| Trifluoroacetic Acid SCHEMBL5636030 | 0.95 | CFTR (0.48) | CFTRKMT2A | |
| SCHEMBL5635489 | 0.93 | CFTR (0.51) | CFTRKMT2A | |
| SCHEMBL6003560 | 0.93 | CFTR (0.51) | CFTRKMT2A | |
| SCHEMBL5635694 | 0.92 | CFTR (0.53) | CFTRKMT2A | |
| SCHEMBL6003573 | 0.92 | CFTR (0.53) | CFTRKMT2A | |
| SCHEMBL6003576 | 0.92 | CFTR (0.50) | CFTRKMT2A | |
| SCHEMBL5634484 | 0.92 | CFTR (0.50) | CFTRKMT2A | |
| SCHEMBL5634918 | 0.91 | CFTR (0.50) | CFTRKMT2A | |
| SCHEMBL5635474 | 0.90 | KMT2A (0.52) | CFTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | claimed |
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006122931-A1 | BETA-CARBOLINE DERIVATIVES AND THERI USE AS GHSR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004765-A1 | New compounds | GHSR, GIPR, PRLHR | CFTR 519/4885KMT2A 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.